Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod in secondary progressive multiple sclerosis
2012-003056-36Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Siponimod with Placebo (2 arms). Primary endpoint: Time to 3-month confirmed disability progression. Started Sep 2012; status: terminated.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2012-003056-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003056-36.